Market Overview

Ariad Pharnaceuticals Continues To Rally

Related ARIA
These Companies Probably Won't Be Acquiring Ariad Pharmaceuticals
ARIAD Offers Updated Clinical Data for Brigatinib in Patients with ALK+ Non-Small Cell Lung Cancer

Following a BMO Capital upgrade to Outperform and price target raised to $14, Ariad Pharmaceuticals (NASDAQ: ARIA) shares are 20% percent higher in Friday's trading at 9.24. Earlier in the session, the issue traded as high as 9.83. That is the highest level for ARIA since it cascaded from 17.14 on October 8, 2013.

Posted-In: Movers & Shakers Technicals Intraday Update Trading Ideas General


Related Articles (ARIA)

Around the Web, We're Loving...